Green Thumb Industries Past Earnings Performance
Past criteria checks 5/6
Green Thumb Industries has been growing earnings at an average annual rate of 35.7%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 36.4% per year. Green Thumb Industries's return on equity is 2.2%, and it has net margins of 3.4%.
Key information
35.7%
Earnings growth rate
38.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 36.4% |
| Return on equity | 2.2% |
| Net Margin | 3.4% |
| Next Earnings Update | 08 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Green Thumb Industries makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,055 | 36 | 336 | 0 |
| 30 Sep 23 | 1,036 | -18 | 328 | 0 |
| 30 Jun 23 | 1,021 | -19 | 326 | 0 |
| 31 Mar 23 | 1,023 | -8 | 305 | 0 |
| 31 Dec 22 | 1,017 | 12 | 293 | 0 |
| 30 Sep 22 | 1,002 | 86 | 282 | 0 |
| 30 Jun 22 | 974 | 96 | 271 | 0 |
| 31 Mar 22 | 942 | 94 | 279 | 0 |
| 31 Dec 21 | 894 | 75 | 272 | 0 |
| 30 Sep 21 | 827 | 75 | 256 | 0 |
| 30 Jun 21 | 751 | 65 | 234 | 0 |
| 31 Mar 21 | 648 | 30 | 212 | 0 |
| 31 Dec 20 | 557 | 15 | 198 | 0 |
| 30 Sep 20 | 455 | -22 | 191 | 0 |
| 30 Jun 20 | 366 | -46 | 172 | 0 |
| 31 Mar 20 | 291 | -54 | 153 | 0 |
| 31 Dec 19 | 216 | -59 | 135 | 0 |
| 30 Sep 19 | 161 | -46 | 112 | 0 |
| 30 Jun 19 | 111 | -35 | 91 | 0 |
| 31 Mar 19 | 79 | -13 | 72 | 0 |
| 31 Dec 18 | 62 | -5 | 52 | 0 |
| 30 Sep 18 | 48 | -7 | 32 | 0 |
| 30 Jun 18 | 35 | -5 | 24 | 0 |
| 31 Mar 18 | 24 | -7 | 15 | 0 |
| 31 Dec 17 | 17 | -4 | 11 | 0 |
| 31 Dec 16 | 7 | -3 | 5 | 0 |
Quality Earnings: R9U2 has high quality earnings.
Growing Profit Margin: R9U2's current net profit margins (3.4%) are higher than last year (1.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: R9U2 has become profitable over the past 5 years, growing earnings by 35.7% per year.
Accelerating Growth: R9U2's earnings growth over the past year (202.8%) exceeds its 5-year average (35.7% per year).
Earnings vs Industry: R9U2 earnings growth over the past year (202.8%) exceeded the Pharmaceuticals industry 2.7%.
Return on Equity
High ROE: R9U2's Return on Equity (2.2%) is considered low.